Łukasz Kuncman

Dr. Łukasz Kuncman

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2024 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
ŁKŁukasz Kuncman
Łukasz Kuncman
MPMatusz Pajdziński
Matusz Pajdziński
KSKrzysztof Smółka
Krzysztof Smółka
MBMateusz Bilski
Mateusz Bilski
JSJoanna Socha
Joanna Socha
JFJacek Fijuth
Jacek Fijuth
Introduction: Radiation induced lymphopenia (RIL) deteriorate survival and diminishes the benefit of immune checkpoint inhibitors in combined treatment of lung cancer. Given the inconsistent data across various studies on the predictors of RIL, we aim to methodically elucidate these predictors and formulate a practical guide for clinicians.Methods: We conducted observational cohort study in four tertiary cancer centers. Patients with non-small cell lung cancer and small cell lung cancer, without lymphopenia grade >1, who underwent standalone radiotherapy (RT) in minimum 15 fractions were eligible. Dose-volume parameters of structures and clinical factors were comprehensively analyzed using various predictors selection methods and statistical models (Linear Regressors, Elastic Net, Bayesian Regressors, Huber Regression, regression based on k-nearest neighbors, Gaussian Process Regressor, Decision Tree Regressor, Random Forest Regressor, eXtreme Gradient Boosting, Automated Machine Learning) and were ranked to predict lymphocytes count nadir (alc_nadir).Results: Two hundred thirty eight patients (stage I-3.4%, II-17.6%, III-75.2%, IV-3.8%) who underwent RT to median dose of 60 Gy were analyzed. Median alc_nadir was 0.68K/mm3. The 60 feature sets were evaluated in 600 models (RMSE 0.27-0.41K/mm³). The most important features were baseline lymphocyte count (alc_1), mean lung_dose, lung v05, lung v10, heart v05 and effective dose to immune cells (edic). In patients with alc_1 ≤ 2.005K/mm3, median alc_nadir predictions were 0.54K/mm3 for lung_v05p > 51.8% and 0.76K/mm3 for lung_v05p ≤ 51.8%. Lymphopenia was rare in patients with alc_1 > 2.005K/mm3.Discussion: RIL was most severe in patients with low early lymphocyte counts, primarily triggered by low RT doses in the heart and lungs.

7 February 2024 in Molecular Oncology
Verified
Journal Article
Open access
ŁKŁukasz Kuncman
Łukasz Kuncman
Magdalena Julita Krystkiewicz-OrzechowskaMagdalena Julita Krystkiewicz-Orzechowska
Magdalena Julita Krystkiewicz-Orzechowska
TMTomasz Milecki
Tomasz Milecki
JKJakub Kucharz
Jakub Kucharz
JFJacek Fijuth
Jacek Fijuth
Most of the currently used cancer immunotherapies inhibit the programmed cell death protein 1 (PD1)–programmed cell death 1 ligand 1 (PDL1) axis of T‐cells. However, dendritic cells (DCs) controlled by natural killer (NK) cells via the FMS‐related tyrosine kinase 3 (FLT3) axis are necessary for activation of T‐cells. The aim of the study was to evaluate FLT3 as a prognostic factor and determine its role in immune infiltration (with emphasis on NK cells and DCs). Using The Cancer Genome Atlas (TCGA) database, we performed bioinformatic analysis of the gene expression datasets of 501 lung squamous cell carcinoma (LUSC) and 515 lung adenocarcinoma (LUAD) patient who had corresponding clinical data [analysis was performed in R (version 4.2.0)]. Disease‐free survival (DFS) differed between the FLT3‐low and FLT3‐high expression groups, respectively, in LUSC (61.0 vs 71.3 months P = 0.075) and LUAD (32.7 vs 47.5 months P = 0.045). A tumor microenvironment (TME) with high immune infiltration and rich in T‐cell exhaustion markers was observed in the FLT3‐high group. We showed overexpression of NK cell and DC gene signatures in the FLT3‐high expression group as well as overexpression of key effector genes of the cyclic GMP‐AMP synthase (cGAS)–stimulator of interferon genes protein (STING) pathway, which is crucial in response to radiotherapy. High expression of FLT3 in the TME was associated with immune cell infiltration (especially of NK cells and DCs), increased expression of T‐cell exhaustion markers and expression of effector genes of the cGAS‐STING pathway, which may consequently increase susceptibility to immunotherapy and radiotherapy. High FLT3 expression correlated with prolonged DFS in the LUSC and LUAD cohorts.

1 January 2016 in Journal of Contemporary Brachytherapy
Verified
Journal Article
Open access
ŁKŁukasz Kuncman
Łukasz Kuncman
SKSławomir Kozłowski
Sławomir Kozłowski
APAndrzej Pietraszek
Andrzej Pietraszek
MPMalwina Pietrzykowska-Kuncman
Malwina Pietrzykowska-Kuncman
JDJustyna Danielska
Justyna Danielska
JFJacek Fijuth
Jacek Fijuth
Purpose : Brachytherapy (BT), due to rapid dose fall off and minor set-up errors, should be superior to external beam radiotherapy (EBRT) for treatment of lesions in difficult locations like nose and earlobe. Evidences in this field are scarce. We describe computed tomography (CT) based surface...

3 July 2020 in Strahlentherapie und Onkologie
Verified
Journal Article
Open access
PDF file
ŁKŁukasz Kuncman
Łukasz Kuncman
Konrad StawiskiKonrad Stawiski
Konrad Stawiski
MMMichał Masłowski
Michał Masłowski
JKJakub Kucharz
Jakub Kucharz
JFJacek Fijuth
Jacek Fijuth
Purpose: Magnetic resonance imaging (MRI) is routinely used for locoregional staging of rectal cancer and offers promise for the prediction of hematologic toxicity. The present study compares the clinical utility of MRI-based active bone marrow (BMact) delineation with that of CT-based bone marrow total (BMtot) delineation for predicting hematologic toxicity. Methods: A prospective cohort study was performed. Eligible patients had stage II/III rectal cancer and qualified for preoperative chemoradiotherapy. The BMact areas on T1-weighted MRI were contoured. The impact of the dose–volume parameters of BMact/BMtot and clinical data on hematologic toxicity were assessed. Basic endpoints were the occurrence of grade 3/4 hematologic toxicity and peripheral blood parameters reaching a nadir. Linear regression models were generated for the nadirs and receiver operating characteristic (ROC) curves for the occurrence of grade 3/4 hematologic toxicity. Results: Thirty-five patients were enrolled. Women presented higher dose–volume parameters of BMact, BMtot, and lymphocyte nadir (ALCnadir%) than men. Models for the prediction of ALCnadir% (V5-V20BMtot, V5-V30BMact) and platelet nadir (PLTnadir%; V5-V10BMtot, V5-V20BMact) were statistically significant. In the ROC curves, a baseline lymphocyte level of 1.81 × 103/ml was adopted as the cutoff for predicting grade 3/4 lymphopenia, with specificity of 77.8% and sensitivity of 73.1%. The multivariate linear regression model for ALCnadir% had R2 = 0.53, p = 0.038. In the tenth step of selection, V5BMact (p = 0.002) and gender (p = 0.019) remained. The multivariate linear regression model for PLTnadir% had R2 = 0.20, p = 0.34. In the sixth step of selection, V15BMact remained (p = 0.026). Conclusion: The dose–volume parameters of BMact serve as better predictors of ALCnadir% and PLTnadir% than BMtot.

18 August 2025 in Radiotherapy and Oncology
Verified
Journal Article
Open access
ŁKŁukasz Kuncman
Łukasz Kuncman
CPCAROLINA DE LA PINTA
CAROLINA DE LA PINTA
MMMaaike T.W. Milder
Maaike T.W. Milder
ARAlejandra Méndèz Romero
Alejandra Méndèz Romero
MGMatthias Guckenberger
Matthias Guckenberger
STStephanie Tanadini-Lang
Stephanie Tanadini-Lang
This systematic review aimed to consolidate current definitions of stereotactic radiotherapy, identify commonly proposed quality standards and address inconsistencies in international practices despite its extensive use. This systematic literature review followed the PRISMA methodology, conducting searches across PubMed, Embase, Cochrane, Scopus, and Epistemonikos databases between January 2001 and April 2024. Eligible articles included those explicitly defining stereotactic radiotherapy or providing detailed implementation criteria. Data extracted covered definitions, staffing needs, technological considerations, and quality assurance procedures. Analysis of 51 articles revealed significant discrepancies in stereotactic radiotherapy definitions and standards. Commonly proposed characteristics included targeting accuracy within ≤ 1 mm for SRS and ≤ 2 mm for SBRT, and high doses per fraction (≥5 Gy per fraction). Fractionation schemes varied extensively, ranging from ≤ 5 fractions (ACR-ASTRO, AAPM Task Group 101) to ≤ 12 fractions (DEGRO). Essential quality measures consistently emphasized multidisciplinary staffing involving radiation oncologists, medical physicists, radiotherapy technologists, and relevant specialists. Technical recommendations frequently highlighted high-resolution imaging methods (e.g., thin-slice CT, 4D CT), precise immobilization techniques, and daily IGRT (CBCT), alongside rigorous quality assurance protocols, including dosimetric validation and equipment checks. Although stereotactic radiotherapy is broadly adopted in daily routine practice, substantial variability exists in its definitions and implementation. This review underscores the need for unified, updated guidelines incorporating contemporary technological advancements and standardized clinical practices to ensure consistent, high-quality patient outcomes.

9 August 2022 in Cancers
Verified
Journal Article
Open access
PDF file
ŁKŁukasz Kuncman
Łukasz Kuncman
Magdalena Julita Krystkiewicz-OrzechowskaMagdalena Julita Krystkiewicz-Orzechowska
Magdalena Julita Krystkiewicz-Orzechowska
Konrad StawiskiKonrad Stawiski
Konrad Stawiski
MMMichał Masłowski
Michał Masłowski
MCMagdalena Ciazynska
Magdalena Ciazynska
JFJacek Fijuth
Jacek Fijuth
The optimal sequence of chemoradiotherapy with immunotherapy is still not established. The patient’s immune status may play a role in determining this order. We aim to determine the kinetics of a multi-potential haemopoietic factor FMS-related tyrosine kinase 3 ligand (Flt-3L) during chemoradiotherapy. Our pilot, a single arm prospective study, enrolled patients with rectal cancer who qualified for neoadjuvant chemoradiotherapy. Blood samples for Flt-3L were collected before and every second week of chemoradiotherapy for a complete blood count every week. The kinetics of Flt-3L were assessed using Friedman’s ANOVA. A multiple factor analysis (MFA) was performed to find relevant factors affecting levels of serum Flt-3L during chemoradiotherapy. FactoMineR and factoextra R packages were used for analysis. In the 33 patients enrolled, the level of Flt-3L increased from the second week and remained elevated until the end of treatment (p < 0.01). All patients experienced Grade ≥2 lymphopenia with a nadir detected mostly in the 5/6th week. MFA revealed the spatial partitioning of patients among the first and second dimensions (explained by 38.49% and 23.14% variance). The distribution along these dimensions represents the magnitude of early changes of Flt-3L. Patients with the lowest values of Flt-3L change showed the highest lymphocyte nadirs and lowest dose/volume parameters of active bone marrow. Our hypothesis-generating study supports the concept of early initiation of immuno-therapy when the concentration of Flt-3L is high and no lymphopenia has yet occurred.